Program
NPT 2042
A development code. Also written as “NPT 2042 (Test formula/Formulation 2)” and “NPT 2042 (Reference formula/Formulation 1)”.
Its studies are mostly in Epilepsy, Absence · Drug Resistant Epilepsy · Epilepsy, led by NeuroPro Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NeuroPro Therapeutics | 30 open or running | phase 2since Dec 23, 2024 | Jul 15, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 15, 2024First study: phase 1 study in Epilepsy, ReflexFirst studyNCT06525649 · 5 enrolled · United States
- Dec 23, 2024Phase 2 study in Epilepsy, GeneralizedNCT06769659 · 14 enrolled · United States
- Oct 13, 2025Phase 1 study in EpilepsyNCT07222878 · 8 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07222878Epilepsy · United States | 1 | Completed | Nov 4, 2025 | 8 |
| NCT06769659Epilepsy, Generalized · United States | 2 | Completed | Aug 17, 2026 | 14 |
| NCT06525649Epilepsy, Reflex · United States | 1 | Completed | Jun 26, 2025 | 5 |
How it is read
Names in the registry
- “NPT 2042”, 2 entries
- “NPT 2042 (Test formula/Formulation 2)”, 2 entries
- “NPT 2042 (Reference formula/Formulation 1)”, 1 entry
Codes read as this program: NPT2042.
Conditions, from the studies’ own filings
- Epilepsy, Absence, 1 study
- Drug Resistant Epilepsy, 1 study
- Epilepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.